<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1248" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1248/" /><meta name="ncbi_pagename" content="Optic Atrophy Type 1 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Optic Atrophy Type 1 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Optic Atrophy Type 1" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/11/12" /><meta name="citation_author" content="Cécile Delettre-Cribaillet" /><meta name="citation_author" content="Christian P Hamel" /><meta name="citation_author" content="Guy Lenaers" /><meta name="citation_pmid" content="20301426" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1248/" /><meta name="citation_keywords" content="Dynamin-like 120 kDa protein, mitochondrial" /><meta name="citation_keywords" content="OPA1" /><meta name="citation_keywords" content="Optic Atrophy Type 1" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Optic Atrophy Type 1" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Cécile Delettre-Cribaillet" /><meta name="DC.Contributor" content="Christian P Hamel" /><meta name="DC.Contributor" content="Guy Lenaers" /><meta name="DC.Date" content="2015/11/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1248/" /><meta name="description" content="Optic atrophy type 1 (OPA1, or Kjer type optic atrophy) is characterized by bilateral and symmetric optic nerve pallor associated with insidious decrease in visual acuity (usually between ages 4 and 6 years), visual field defects, and color vision defects. Visual impairment is usually moderate (6/10 to 2/10), but ranges from mild or even insignificant to severe (legal blindness with acuity &lt;1/20). The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia). Other findings can include auditory neuropathy resulting in sensorineural hearing loss that ranges from severe and congenital to subclinical (i.e., identified by specific audiologic testing only)." /><meta name="og:title" content="Optic Atrophy Type 1" /><meta name="og:type" content="book" /><meta name="og:description" content="Optic atrophy type 1 (OPA1, or Kjer type optic atrophy) is characterized by bilateral and symmetric optic nerve pallor associated with insidious decrease in visual acuity (usually between ages 4 and 6 years), visual field defects, and color vision defects. Visual impairment is usually moderate (6/10 to 2/10), but ranges from mild or even insignificant to severe (legal blindness with acuity &lt;1/20). The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia). Other findings can include auditory neuropathy resulting in sensorineural hearing loss that ranges from severe and congenital to subclinical (i.e., identified by specific audiologic testing only)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1248/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/opa/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1248/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DD866E04079410000000006120239.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1248_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1248_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/opmd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ofd1/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1248_"><span class="title" itemprop="name">Optic Atrophy Type 1</span></h1><p class="contrib-group"><span itemprop="author">C&#x000e9;cile Delettre-Cribaillet</span>, PhD, <span itemprop="author">Christian P Hamel</span>, MD, and <span itemprop="author">Guy Lenaers</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1248_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1248_ai__"><div class="contrib half_rhythm"><span itemprop="author">C&#x000e9;cile Delettre-Cribaillet</span>, PhD<div class="affiliation small">Inserm U1051<br />INM H&#x000f4;pital Saint Eloi<br />Montpellier, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.mresni@ertteled.elicec" class="oemail">rf.mresni@ertteled.elicec</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Christian P Hamel</span>, MD<div class="affiliation small">Inserm U1051<br />INM H&#x000f4;pital Saint Eloi<br />Montpellier, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.mresni@lemah.naitsirhc" class="oemail">rf.mresni@lemah.naitsirhc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Guy Lenaers</span>, PhD<div class="affiliation small">UMR CNRS 6214<br />Inserm U1083<br />Centre Hospitalier Universitaire<br />Angers, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.mresni@sreanel.yug" class="oemail">rf.mresni@sreanel.yug</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 13, 2007</span>; Last Update: <span itemprop="dateModified">November 12, 2015</span>.</p><p><em>Estimated reading time: 24 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="opa.Summary" itemprop="description"><h2 id="_opa_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Optic atrophy type 1 (OPA1, or Kjer type optic atrophy) is characterized by bilateral and symmetric optic nerve pallor associated with insidious decrease in visual acuity (usually between ages 4 and 6 years), visual field defects, and color vision defects. Visual impairment is usually moderate (6/10 to 2/10), but ranges from mild or even insignificant to severe (legal blindness with acuity &#x0003c;1/20). The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia). Other findings can include auditory neuropathy resulting in sensorineural hearing loss that ranges from severe and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> to subclinical (i.e., identified by specific audiologic testing only).</p><p>Visual evoked potentials are typically absent or delayed; pattern electroretinogram shows an abnormal N95:P50 ratio. Tritanopia is the classic feature of color vision defect, but more diffuse nonspecific dyschromatopsia is not uncommon. Ophthalmoscopic examination discloses temporal or diffuse pallor of the optic discs, sometimes associated with optic disc excavation. The neuroretinal rim shows some pallor in most cases, sometimes associated with a temporal pigmentary gray crescent.</p></div><div><h4 class="inline">Diagnosis.</h4><p>The diagnosis of OPA1 is made based on a combination of clinical findings, electrophysiologic studies, and family history and/or by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OPA1</i>, the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> known to be associated with OPA1, by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Low-vision aids for decreased visual acuity.</p><p><i>Surveillance:</i> Annual ophthalmologic evaluations (including measurement of visual acuity, visual fields, and optical coherence tomography) and hearing evaluations.</p><p><i>Agents/circumstances to avoid:</i> Smoking, excessive alcohol intake, medications (antibiotics, antivirals) that interfere with mitochondrial metabolism.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>OPA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Most individuals diagnosed with OPA1 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; however, <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have been reported. Each child of an individual with OPA1 has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant has been identified in an affected family member, but <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> remains complicated by the incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> and the markedly variable inter- and intrafamilial expressivity of the disease.</p></div></div><div id="opa.Diagnosis"><h2 id="_opa_Diagnosis_">Diagnosis</h2><div id="opa.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Optic atrophy type 1 (OPA1 or Kjer type optic atrophy) <b>should be suspected</b> in individuals with the following clinical, electrophysiologic, and family history findings:</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Childhood onset</div></li><li class="half_rhythm"><div class="half_rhythm">Bilateral vision loss that is usually symmetric</div></li><li class="half_rhythm"><div class="half_rhythm">Visual field defect that is typically centrocecal, central, or paracentral</div></li><li class="half_rhythm"><div class="half_rhythm">Peripheral field that is usually normal, although inversion of red and blue isopters may occur.</div><div class="half_rhythm">Note: The isopters are lines joining points of equal sensitivity on a visual field chart. The red isopter represents the largest/brightest stimulus; the blue isopter represents the smallest/dimmest stimulus. Persons with OPA1 have scotomas (areas of impaired visual acuity) in the central visual fields and sparing of the peripheral visual fields.</div></li><li class="half_rhythm"><div class="half_rhythm">Color vision defect, often described as acquired blue-yellow loss (tritanopia)</div></li><li class="half_rhythm"><div class="half_rhythm">Opthalmoscopic examination that demonstrates:</div><ul><li class="half_rhythm"><div>Optic nerve pallor (the cardinal sign) that is most often bilateral and symmetric, but may be temporal (50% of individuals) and global (50%) [<a class="bk_pop" href="#opa.REF.votruba.2003.48">Votruba et al 2003</a>];</div></li><li class="half_rhythm"><div>Profound papillary excavation (21% of eyes with OPA1) [<a class="bk_pop" href="#opa.REF.alward.2003.2">Alward 2003</a>];</div></li><li class="half_rhythm"><div>Neuroretinal rim pallor in most cases, sometimes associated with a temporal pigmentary gray crescent.</div></li></ul></li></ul><p><b>Electrophysiology</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Visual evoked potentials (VEPs) are typically absent or delayed, indicating a conduction defect in the optic nerve.</div></li><li class="half_rhythm"><div class="half_rhythm">Pattern electroretinogram (PERG) shows an abnormal N95:P50 ratio, with reduction in the amplitude of the N95 waveform [<a class="bk_pop" href="#opa.REF.holder.1998.217">Holder et al 1998</a>]. Since the N95 component of the PERG is thought to be specific for the retinal ganglion cell, this finding supports a ganglion cell origin for the optic atrophy.</div><div class="half_rhythm">Note: The PERG originates from the inner retinal layers, enabling an assessment of ganglion cell function, and is increasingly used in the assessment of anterior visual pathway dysfunction. The normal PERG consists of a prominent positive peak at 50 ms (P50), and a slow, broad trough with a minimum at 95 ms (N95). The positive P50 component is invariably <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> in retinal and macular dysfunction, whereas the negative N95 component is principally affected in optic nerve disease. Furthermore, the ratio between N95 and P50 has been shown to be an effective measure of retinal ganglion cell function.</div></li></ul><p><b>Family history</b> consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</p><p>Note: Absence of a family history of OPA1 does not preclude the diagnosis.</p></div><div id="opa.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of optic atrophy type 1 (OPA1) <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical findings and/or a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OPA1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1248/table/opa.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figopaTmoleculargenetictestingusedin" rid-ob="figobopaTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div>Targeted analysis for the <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.2826delT</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be performed first in individuals of Danish ancestry.</div></li><li class="half_rhythm"><div>In individuals who are not of Danish ancestry or if targeted analysis does not identify a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>OPA1</i> is performed, followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no pathogenic variant is found.</div></li><li class="half_rhythm"><div>If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>OPA3</i> for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy type 3 (OPA3) and for the common mitochondrial DNA (mtDNA) single-nucleotide pathogenic variants responsible for <a href="/books/n/gene/lhon/">Leber hereditary optic neuropathy</a> (LHON) should be considered (see <a href="#opa.Differential_Diagnosis">Differential Diagnosis</a>).</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>OPA1</i> and other genes of interest (see <a href="#opa.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>, and mitochondrial sequencing may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) fails to confirm a diagnosis in an individual with features of optic atrophy type 1.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="opa.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Optic Atrophy Type 1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1248/table/opa.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opa.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr><tr><th headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Familial</th><th headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Simplex&#x000a0;<sup>3</sup></th></tr></thead><tbody><tr><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>OPA1</i></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/9&#x000a0;<sup>5</sup><br />10/14&#x000a0;<sup>6</sup><br />17/19&#x000a0;<sup>7</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/8&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>8</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>9</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>10</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>11</sup></td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_opa.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_opa.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="opa.TF.1.1"><p class="no_margin">See <a href="/books/NBK1248/#opa.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="opa.TF.1.2"><p class="no_margin">See <a href="#opa.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="opa.TF.1.3"><p class="no_margin">Simplex = a single occurrence in a family</p></div></dd><dt>4. </dt><dd><div id="opa.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="opa.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#opa.REF.nakamura.2006.483">Nakamura et al [2006]</a> found <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>OPA1</i> pathogenic variants in 8/9 <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases and 4/8 <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases. Of note, on examination of family members of two apparently simplex cases, <a class="bk_pop" href="#opa.REF.nakamura.2006.483">Nakamura et al [2006]</a> found heterozygous <i>OPA1</i> pathogenic variants in relatives with a normal or only mildly abnormal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, supporting the notions of <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> and reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div></dd><dt>6. </dt><dd><div id="opa.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#opa.REF.puomila.2005.337">Puomila et al [2005]</a></p></div></dd><dt>7. </dt><dd><div id="opa.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#opa.REF.delettre.2001.584">Delettre et al [2001]</a></p></div></dd><dt>8. </dt><dd><div id="opa.TF.1.8"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>9. </dt><dd><div id="opa.TF.1.9"><p class="no_margin">A ~325-bp <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> resulting in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping has been reported [<a class="bk_pop" href="#opa.REF.gallus.2010.178">Gallus et al 2010</a>]. See <a href="#opa.Molecular_Genetics">Molecular Genetics</a>.</p></div></dd><dt>10. </dt><dd><div id="opa.TF.1.10"><p class="no_margin">Detects the Danish founder pathogenic <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.2826delT</a> variant. Note: Pathogenic variants included in a panel may vary by laboratory.</p></div></dd><dt>11. </dt><dd><div id="opa.TF.1.11"><p class="no_margin">Because the detection rate for pathogenic variants in <i>OPA1</i> is less than 100%, it is possible that families in which a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not detected are not linked to the <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>; however, no evidence currently supports this possibility.</p></div></dd></dl></div></div></div></div></div><div id="opa.Clinical_Characteristics"><h2 id="_opa_Clinical_Characteristics_">Clinical Characteristics</h2><div id="opa.Clinical_Description"><h3>Clinical Description</h3><p><b>Vision loss.</b> OPA1 usually presents as insidious decrease in visual acuity between ages four and six years; in mild cases visual acuity may remain normal until early adult life. Visual acuity usually declines slowly with age. Although rare, rapid decline in visual acuity has been reported in adults [<a class="bk_pop" href="#opa.REF.kjer.1996.3">Kjer et al 1996</a>].</p><p>The visual impairment is usually moderate (6/10 to 2/10), but ranges from severe (legal blindness with acuity &#x0003c;1/20) to mild or even insignificant, and consequently can be underestimated.</p><p>The vision loss is occasionally asymmetric.</p><p>The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia).</p><p>Typical OPA1 is associated with a progressive and irreversible loss of vision. However, <a class="bk_pop" href="#opa.REF.cornille.2008.667">Cornille et al [2008]</a> reported a man age 23 years who developed unexplained <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a>, progressive, painless bilateral optic neuropathy as a result of central scotomas (visual acuity 20/200 in the right eye and 20/100 in the left eye) three months after the first signs of visual loss. Six months later he had spontaneous and durable partial recovery of visual acuity (20/30 in the right eye and 20/25 in the left eye). He was the first <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual described with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the three alternative <i>OPA1</i> exons (see <a href="#opa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><p><b>Extra-ophthalmogic findings.</b> Up to 10% of persons with a heterozgyous <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have additional extra-ophthalmologic abnormalities, most commonly sensorineural hearing loss, ataxia, and myopathy, suggesting that pathogenic variants in <i>OPA1</i> may be responsible for a continuum of phenotypes ranging from mild disorders affecting only the retinal ganglion cells to a severe and multisystemic disease.</p><p><b>Sensorineural hearing loss</b> that ranges from severe and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> to subclinical (requiring specific testing for detection) is the most frequently extra-ocular feature observed. Such hearing loss appears to be due to auditory neuropathy [<a class="bk_pop" href="#opa.REF.amatibonneau.2005.958">Amati-Bonneau et al 2005</a>]. Seven pathogenic variants in <i>OPA1</i> have been found to be associated with optic atrophy and hearing loss (see <a href="#opa.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>). Both intra- and interfamilial variation in the presence of hearing loss with optic atrophy has been observed.</p><p><b>Ataxia</b> and <b>myopathy.</b> Some individuals developed proximal myopathy (35%), a combination of cerebellar and sensory ataxia in adulthood (29%), and axonal sensory and/or motor neuropathy (29%). These features became manifest from the third decade of life onwards.</p><p>Muscle biopsy revealed features diagnostic of mitochondrial myopathy. In these individuals approximately 10% of all fibers were deficient in histochemical COX activity and several fibers showed evidence of subsarcolemmal accumulation of abnormal mitochondria.</p><p><b>Pathology</b></p><ul><li class="half_rhythm"><div>The cardinal sign of OPA1 is optic atrophy that appears as bilateral and generally symmetric temporal pallor of the optic disc, implying the loss of central retinal ganglion cells.</div></li><li class="half_rhythm"><div>Histopathology shows a normal outer retina and loss of retinal ganglion cells, primarily in the macula and in the papillo-macular bundle of the optic nerve.</div></li></ul></div><div id="opa.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No correlation has been observed between the degree of visual impairment and the location or type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#opa.REF.puomila.2005.337">Puomila et al 2005</a>].</p><p>Complete <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>OPA1</i> results in typical dominant optic atrophy without predictable severity or other deficits [<a class="bk_pop" href="#opa.REF.marchbank.2002.e47">Marchbank et al 2002</a>]. However, it appears that pathogenic <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions involve loss of visual acuity (1/10 on average) that is statistically slightly more severe than that resulting from pathogenic truncating variants or pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> substitutions (2/10 on average) [Ait Ali et al, unpublished].</p><p><b>Optic atrophy</b> and <b>hearing loss.</b> Seven different pathogenic variants in <i>OPA1</i> have been reported in individuals with both optic atrophy and hearing loss: <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg445His</a>, <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Gly401Asp</a>, <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Leu243Ter</a>, <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.983A&#x0003e;G</a>, <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Ile463_Phe464dup</a>, <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Gln437Arg</a>, and <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Ala357LeufsTer4</a> [<a class="bk_pop" href="#opa.REF.leruez.2013.e236">Leruez et al 2013</a>].</p><ul><li class="half_rhythm"><div>In an individual with the <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg445His</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, auditory brain stem responses (ABRs) were absent and both ears had normal evoked otoacoustic emissions [<a class="bk_pop" href="#opa.REF.amatibonneau.2005.958">Amati-Bonneau et al 2005</a>]. Because evoked otoacoustic emissions reflect the functional state of presynaptic elements (the outer hair cells), and the ABRs reflect the integrity of the auditory pathway from the auditory nerve to the inferior colliculus, the presence of evoked otoacoustic emissions and the lack of ABRs support the diagnosis of auditory neuropathy.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#opa.REF.treft.1984.908">Treft et al [1984]</a> and <a class="bk_pop" href="#opa.REF.meire.1985.91">Meire et al [1985]</a> reported two unrelated families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy, hearing loss, ptosis, and ophthalmoplegia. Subsequent studies revealed the <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg445His</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OPA1</i> in both families [<a class="bk_pop" href="#opa.REF.payne.2004.749">Payne et al 2004</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#opa.REF.li.2005.208">Li et al [2005]</a> identified the <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg445His</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a family with optic atrophy and hearing loss, without ptosis or ocular motility abnormalities. These family members are also myopic, but it is not clear whether myopia is part of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>In contrast, the <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg445His</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was associated with optic atrophy <b>without</b> hearing loss in a Japanese individual age 21 years; no other family member was clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or had the <i>OPA1</i> pathogenic variant [<a class="bk_pop" href="#opa.REF.shimizu.2003.256">Shimizu et al 2003</a>].</div></li></ul><p><b>Alternate <i>OPA1</i> transcripts.</b>
<a class="bk_pop" href="#opa.REF.cornille.2008.667">Cornille et al [2008]</a> reported a young man with unexplained <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a>, progressive, painless bilateral optic neuropathy as a result of central scotomas (see <a href="#opa.Clinical_Description">Clinical Description</a>, <b>Visual loss</b>) who harbored a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5b (<a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.740G&#x0003e;A</a>). This was the first report of a pathogenic variant in one of the three alternative <i>OPA1</i> exons, leading to an amino acid change in the N-terminal coiled coil <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (<a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">p.Arg247His</a>) from isoform 8. This individual had spontaneous and durable partial recovery of visual acuity (20/30 in the right eye and 20/25 in the left eye) six months later.</p></div><div id="opa.Penetrance"><h3>Penetrance</h3><p>The estimated <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of 98% in OPA1 has been revised in the light of molecular genetic studies. Penetrance varies from family to family and <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to pathogenic variant. It has been reported as high as 100% (variant <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.1065+1G&#x0003e;T</a>, resulting in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 12 skipping) [<a class="bk_pop" href="#opa.REF.thiselton.2002.1715">Thiselton et al 2002</a>] and as low as 43% (variant <a class="figpopup" href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figopaTopa1pathogenicvariantsdiscussed" rid-ob="figobopaTopa1pathogenicvariantsdiscussed">c.2708_2711delTTAG</a> in exon 27) [<a class="bk_pop" href="#opa.REF.toomes.2001.1369">Toomes et al 2001</a>]. In these two studies the clinical diagnosis was made on the basis of reduced visual acuity, abnormal color discrimination, fundus examination showing temporal pallor of the optic disc, and electrophysiology studies [<a class="bk_pop" href="#opa.REF.toomes.2001.1369">Toomes et al 2001</a>, <a class="bk_pop" href="#opa.REF.thiselton.2002.1715">Thiselton et al 2002</a>].</p></div><div id="opa.Nomenclature"><h3>Nomenclature</h3><p>Optic atrophy type 1 was formerly known as Kjer type optic atrophy.</p></div><div id="opa.Prevalence"><h3>Prevalence</h3><p>OPA1 is believed to be the most common of the hereditary optic neuropathies.</p><p>The estimated prevalence of OPA1 is 1:50,000 in most populations, or as high as 1:10,000 in Denmark. The relatively high frequency of OPA1 in Denmark may be attributable to a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> [<a class="bk_pop" href="#opa.REF.thiselton.2002.1715">Thiselton et al 2002</a>].</p></div></div><div id="opa.Genetically_Related_Allelic_Disorder"><h2 id="_opa_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>OPA1</i>.</p></div><div id="opa.Differential_Diagnosis"><h2 id="_opa_Differential_Diagnosis_">Differential Diagnosis</h2><p><b><i>OPA3.</i></b>
<i>OPA3</i> consists of three exons and encodes for an inner mitochondrial membrane protein. The function of this protein is not well known. Two disorders are associated with pathogenic variants in <i>OPA3</i>:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/mga3/"><b>Costeff optic atrophy syndrome</b></a>
<b>(3-methylglutaconic aciduria type 3).</b> Pathogenic truncating variants are responsible for this neuroophthalmologic syndrome consisting of early-onset bilateral optic atrophy and later-onset spasticity, extrapyramidal dysfunction, and cognitive deficit. Urinary excretion of 3-methylglutaconic acid and of 3-methglutaric acid is increased. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Autosomal optic atrophy and cataract (ADOAC, OPA3)</b> (OMIM <a href="http://omim.org/entry/165300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">165300</a>). <a class="bk_pop" href="#opa.REF.reynier.2004.e110">Reynier et al [2004]</a> have identified two pathogenic variants in <i>OPA3</i> (p.Gly93Ser and p.Gln105Glu) that change one of the amino acids. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li></ul><p><a href="/books/n/gene/lhon/"><b>Leber hereditary optic neuropathy</b></a>
<b>(LHON)</b> is the major differential diagnosis for optic atrophy type 1 (OPA1). LHON typically presents in young adults as painless subacute bilateral visual failure. Males are more commonly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than females. Women tend to develop the disorder slightly later in life and may be more severely affected. The acute phase begins with blurring of central vision and color desaturation that affect both eyes simultaneously in up to 25% of cases. After the initial symptoms, both eyes are usually affected within six months. The central visual acuity deteriorates to the level of counting fingers in the majority of cases. After the acute phase, the optic discs become atrophic. Significant improvements in visual acuity are rare. Individuals then proceed into the atrophic phase and are usually legally blind for the rest of their lives with a permanent large centrocecal scotoma. Neurologic abnormalities such as postural tremor, peripheral neuropathy, nonspecific myopathy, and movement disorders have been reported to be more common in individuals with LHON than in controls. Some individuals with LHON, usually women, also have a multiple sclerosis (MS)-like illness.</p><p>LHON is transmitted by maternal inheritance. In one large study, 90% of individuals with LHON were found to have one of three pathogenic variants in mtDNA: m.11778G&#x0003e;A, m.14484T&#x0003e;C, m.3460G&#x0003e;A.</p><p><b>Autosomal dominant optic atrophy (ADOA).</b> Two other loci associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy have been identified:</p><ul><li class="half_rhythm"><div>OPA4 (OMIM <a href="http://www.omim.org/entry/605293" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605293</a>) was mapped to 8q12.2-q12.3 in a single large family by <a class="bk_pop" href="#opa.REF.kerrison.1999.805">Kerrison et al [1999]</a>; however, the <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> has not been confirmed and the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is causative is unknown.</div></li><li class="half_rhythm"><div>OPA5 (OMIM <a href="http://omim.org/entry/610708" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610708</a>) was mapped to 22q12.1-q13.1 by <a class="bk_pop" href="#opa.REF.barbet.2005.e1">Barbet et al [2005]</a> in two unrelated families.</div></li></ul><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the three families with OPA4 or OPA5 is comparable to the phenotype seen in OPA1: optic nerve pallor, decreased visual acuity, color vision defects, impaired VEP, and normal ERG. No extraocular findings were described in these families.</p><p>Another OPA <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> for <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy (OPA8) was mapped to 16q21-q22 in one Italian family with extraophthalmologic features extending to the auditory system [<a class="bk_pop" href="#opa.REF.carelli.2007.a42">Carelli et al 2007</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is causative is unknown.</p><p><a href="/books/n/gene/ddon/"><b>Deafness-dystonia-optic neuronopathy syndrome</b></a>
<b>(DDON).</b> Males with DDON have prelingual or postlingual sensorineural hearing impairment in early childhood, slowly progressive dystonia or ataxia in the teens, slowly progressive decreased visual acuity from optic atrophy beginning about age 20 years, and dementia beginning at about age 40 years. Psychiatric symptoms such as personality change and paranoia may appear in childhood and progress. The hearing impairment <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is a progressive auditory neuropathy, while the neurologic, visual, and neuropsychiatric signs vary in degree of severity and rate of progression. Females may have mild hearing impairment and focal dystonia.</p><p>Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>. The DDON syndrome occurs as either a single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> disorder resulting from pathogenic variants in <i>TIMM8A</i> or a <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion-syndrome/">contiguous gene deletion syndrome</a> at Xq22, which also includes <a href="/books/n/gene/xla/">X-linked agammaglobulinemia</a> caused by disruption of <i>BTK</i>, located telomeric to <i>TIMM8A</i>.</p><p><b><i>WFS1</i>.</b> Biallelic pathogenic variants in <i>WFS1</i> are generally associated with optic atrophy (OPA) as part of the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Wolfram syndrome <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (DIDMOAD [<i>d</i>iabetes <i>i</i>nsipidus, <i>d</i>iabetes <i>m</i>ellitus, <i>o</i>ptic <i>a</i>trophy, <i>d</i>eafness]). Heterozygous pathogenic variants in <i>WFS1</i> cause <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> progressive low-frequency sensorineural hearing loss (LFSNHL) without ophthalmologic abnormalities [<a class="bk_pop" href="#opa.REF.cryns.2003.275">Cryns et al 2003</a>]. However, <a class="bk_pop" href="#opa.REF.eiberg.2006.435">Eiberg et al [2006]</a> identified a <i>WFS1</i> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> associated with autosomal dominant optic atrophy, hearing loss, and impaired glucose regulation in one family, supporting the notion that heterozygous pathogenic variants in <i>WFS1</i> as well as in <i>OPA1</i> may lead to optic atrophy combined with hearing impairment (see <a href="/books/n/gene/wfs/"><i>WFS1</i>-Related Disorders</a>).</p><p><b><i>MFN2</i>.</b>
<a href="/books/n/gene/cmt2a/">Charcot-Marie-Tooth (CMT) neuropathy type 2A</a> with visual impairment resulting from optic atrophy has been designated as hereditary motor and sensory neuropathy type VI (HMSN VI) [<a class="bk_pop" href="#opa.REF.voo.2003.670">Voo et al 2003</a>]. <a class="bk_pop" href="#opa.REF.z_chner.2006.276">Z&#x000fc;chner et al [2006]</a> described six families with HMSN VI with a subacute onset of optic atrophy and subsequent slow recovery of visual acuity in 60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. In each <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> a unique <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MFN2</i>, encoding mitofusin 2, was identified. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</p><p><b>Other optic neuropathies.</b> The acquired blue-yellow loss (tritanopia) helps differentiate OPA1 from other optic neuropathies in which the axis of confusion is red-green:</p><ul><li class="half_rhythm"><div><b>OPA2</b> (OMIM <a href="http://omim.org/entry/311050" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">311050</a>). A <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> optic atrophy (OPA2) has been mapped to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> Xp11.4-p11.21; to date no gene has been identified.</div></li><li class="half_rhythm"><div><b>OPA6</b> (OMIM <a href="http://omim.org/entry/258500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">258500</a>). The first <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> for <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> optic atrophy (ROA1) has been mapped to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 8q. Dyschromatopsia for red-green confusion occurs in OPA6.</div></li><li class="half_rhythm"><div><b>OPA7</b> (OMIM <a href="http://omim.org/entry/612989" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612989</a>). <a class="bk_pop" href="#opa.REF.hanein.2009.493">Hanein et al [2009]</a> identified an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> juvenile-onset optic atrophy in a large multiplex <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> Algerian family and subsequently in three other Maghreb families. This form of optic atrophy is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TMEM126A</i>, which encodes a mitochondrial protein found in higher eukaryotes that has four transmembrane domains and a central <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> conserved with the related protein encoded by <i>TMEM126B</i>.</div></li></ul><p><b>Acquired optic neuropathy</b> can be caused by the following:</p><ul><li class="half_rhythm"><div>Nutritional deficiencies of protein, or of the B vitamins and folate, associated with starvation, malabsorption, or alcoholism</div></li><li class="half_rhythm"><div>Toxic exposures. The most common is "tobacco-alcohol amblyopia," thought to be caused by exposure to cyanide from tobacco smoking, and by low levels of vitamin B<sub>12</sub> caused by poor nutrition and poor absorption associated with drinking alcohol. Other possible toxins include ethambutol, methyl alcohol, ethylene glycol, cyanide, lead, and carbon monoxide.</div></li><li class="half_rhythm"><div>Certain medications</div></li></ul><p>See <a href="http://omim.org/phenotypicSeries/PS165500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Optic atrophy: OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div><div id="opa.Management"><h2 id="_opa_Management_">Management</h2><div id="opa.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual with optic atrophy type 1 (OPA1), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Assessment of visual acuity, color vision, and visual fields</div></li><li class="half_rhythm"><div>Assessment of extraocular muscles (the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is asked to follow the ophthalmoscope with his/her eyes without moving the head)</div></li><li class="half_rhythm"><div>Hearing evaluation: auditory brain stem responses (ABRs), auditory evoked potentials (AEPs), and evoked otoacoustic emissions</div></li><li class="half_rhythm"><div>Oral glucose tolerance test</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="opa.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No treatment for OPA1 is of proven efficacy.</p><p>Treatment of decreased visual acuity is symptomatic (e.g., low-vision aids).</p><p>For treatment of sensorineural hearing loss, see <a href="/books/n/gene/deafness-overview/">Hereditary Hearing Loss and Deafness Overview</a>.</p><p>For treatment of ataxia, see <a href="/books/n/gene/ataxias/">Ataxia Overview</a>.</p></div><div id="opa.Surveillance"><h3>Surveillance</h3><p>Appropriate surveillance includes:</p><ul><li class="half_rhythm"><div>Annual ophthalmologic examination, including measurement of visual acuity and visual fields and optical coherence tomography (OCT);</div></li><li class="half_rhythm"><div>Annual hearing evaluation.</div></li></ul></div><div id="opa.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Individuals with an <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are advised:</p><ul><li class="half_rhythm"><div>Not to smoke;</div></li><li class="half_rhythm"><div>To moderate their alcohol intake;</div></li><li class="half_rhythm"><div>To use sunglasses to limit UV exposure;</div><div>Note: While limiting UV exposure is a good practice, no evidence for its effectiveness exists.</div></li><li class="half_rhythm"><div>To avoid medications (antibiotics, antivirals) that interfere with mitochondrial metabolism.</div></li></ul></div><div id="opa.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#opa.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="opa.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A study using the antioxidant EPI-743 in individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy (ADOA), including persons with OPA1, is in preparation in Italy (Dr. Valerio Carelli, University of Bologna).</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="opa.Genetic_Counseling"><h2 id="_opa_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="opa.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Optic atrophy type 1 (OPA1) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="opa.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with OPA1 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with OPA1 may have the disorder as the result of a <i>de novo OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><ul><li class="half_rhythm"><div>Two instances of <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have been reported [<a class="bk_pop" href="#opa.REF.baris.2003.656">Baris et al 2003</a>].</div></li><li class="half_rhythm"><div>In a report of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in 980 persons for suspected hereditary optic neuropathies, about half of those identified as having a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) [<a class="bk_pop" href="#opa.REF.ferr_.2009.e692">Ferr&#x000e9; et al 2009</a>].</div></li></ul></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> mutation in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include: (1) ophthalmologic evaluation including an assessment of visual acuity, color vision, and visual fields; and (2) audiologic examinations consisting of auditory brain stem responses (ABRs), auditory evoked potentials (AEP) recordings, and study of evoked otoacoustic emissions.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with OPA1 may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disorder in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are found on the basis of visual acuity study, color vision evaluation, fundus examination, VEP, and PERG to be clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for OPA1 because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with OPA1 is at a 50% risk of inheriting the <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents.</div></li><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</div></li></ul></div><div id="opa.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with optic atrophy type 1 has the <i>OPA1</i> pathogenic variant or clinical evidence of the disorder based on visual acuity study, color vision evaluation, fundus examination, VEP, and PERG, the <i>OPA1</i> pathogenic variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="opa.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for OPA1 are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="opa.Resources"><h2 id="_opa_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Foundation Fighting Blindness</b></div><div>7168 Columbia Gateway Drive</div><div>Suite 100</div><div>Columbia MD 21046</div><div><b>Phone:</b> 800-683-5555 (toll-free); 800-683-5551 (toll-free TDD); 410-423-0600</div><div><b>Email:</b> info@fightblindness.org</div><div><a href="https://www.fightingblindness.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fightingblindness.org</a></div></li><li class="half_rhythm"><div><b>National Eye Institute</b></div><div>31 Center Drive</div><div>MSC 2510</div><div>Bethesda MD 20892-2510</div><div><b>Phone:</b> 301-496-5248</div><div><b>Email:</b> 2020@nei.nih.gov</div><div><a href="https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/low-vision" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Low Vision</a></div></li><li class="half_rhythm"><div><b>National Federation of the Blind (NFB)</b></div><div>200 East Wells Street</div><div>(at Jernigan Place)</div><div>Baltimore MD 21230</div><div><b>Phone:</b> 410-659-9314</div><div><b>Fax:</b> 410-685-5653</div><div><b>Email:</b> pmaurer@nfb.org</div><div><a href="http://www.nfb.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nfb.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li></ul></div><div id="opa.Molecular_Genetics"><h2 id="_opa_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="opa.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Optic Atrophy Type 1: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1248/table/opa.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opa.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_opa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_opa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_opa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_opa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_opa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_opa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_opa.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4976" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>OPA1</i></a></td><td headers="hd_b_opa.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4976" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q29</a></td><td headers="hd_b_opa.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O60313" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dynamin-like 120 kDa protein, mitochondrial</a></td><td headers="hd_b_opa.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.retina-international.org/files/sci-news/opa1mut.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retina International Mutations of the Optic Atrophy 1 Gene (OPA1)</a><br /><a href="https://databases.lovd.nl/shared/genes/OPA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA1 database</a></td><td headers="hd_b_opa.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=OPA1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA1</a></td><td headers="hd_b_opa.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=OPA1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="opa.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="opa.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Optic Atrophy Type 1 (<a href="/omim/165500,605290" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1248/table/opa.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opa.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/165500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">165500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OPTIC ATROPHY 1; OPA1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/605290" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">605290</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OPA1 GENE; OPA1</td></tr></tbody></table></div></div><div id="opa.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Because <i>OPA1</i> expression is ubiquitous, and it was recently proposed that neither the pattern nor the abundance of <i>OPA1</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> and dynamin-like 120-kd protein variants are specific to retinal ganglion cell (RGC) [<a class="bk_pop" href="#opa.REF.kamei.2005.4288">Kamei et al 2005</a>], a plausible hypothesis as to why these neurons may be more vulnerable to <i>OPA1</i> inactivation could be a particular susceptibility to mitochondrial membrane disorders inducing mitochondrial dysfunction or mislocalization. While the former point is in agreement with reports that describe altered mitochondrial ATP synthesis and respiration in <i>OPA1</i>-inactivated cells [<a class="bk_pop" href="#opa.REF.lodi.2004.719">Lodi et al 2004</a>, <a class="bk_pop" href="#opa.REF.amatibonneau.2005.958">Amati-Bonneau et al 2005</a>, <a class="bk_pop" href="#opa.REF.chen.2005.26185">Chen et al 2005</a>], the latter may relate to the particular distribution of the mitochondria in retinal ganglion cells. These show an accumulation of mitochondria in the cell bodies and in the intraretinal unmyelinated axons, where they accumulate in the varicosities, and a relative paucity of mitochondria in the myelinated parts of axons [<a class="bk_pop" href="#opa.REF.andrews.1999.231">Andrews et al 1999</a>, <a class="bk_pop" href="#opa.REF.bristow.2002.791">Bristow et al 2002</a>, <a class="bk_pop" href="#opa.REF.wang.2003.2">Wang et al 2003</a>]. Furthermore, the effect of mitochondrial dynamics on the correct intracellular distribution of the mitochondria and its influence on neuronal plasticity and function was recently highlighted by inactivation of <i>DRP1</i> in live hippocampal neurons [<a class="bk_pop" href="#opa.REF.li.2004.873">Li et al 2004</a>]. A link between axonal transport of mitochondria [<a class="bk_pop" href="#opa.REF.hollenbeck.2005.5411">Hollenbeck &#x00026; Saxton 2005</a>] and mitochondrial dynamics was also enlightened by a recent study showing that <i>Drosophila</i> mutants lacking the ortholog of human DRP1 protein failed to populate the distal axon with mitochondria, affecting the mobilization of the synaptic vesicle reserve pool [<a class="bk_pop" href="#opa.REF.hollenbeck.2005.331">Hollenbeck 2005</a>]. Moreover, pathogenic variants in the pro-fusion protein encoded by <i>MFN2</i>, which cause a peripheral neuropathy (see <a href="/books/n/gene/cmt2a/">CMT2A</a>) [<a class="bk_pop" href="#opa.REF.z_chner.2006.276">Z&#x000fc;chner et al 2006</a>], significantly impaired the transport of mitochondria in axons in neurons expressing disease-causing forms of <i>MFN2</i> [<a class="bk_pop" href="#opa.REF.baloh.2007.422">Baloh et al 2007</a>]. These data suggest that proper localization of mitochondria is critical for axonal and synaptic function.</p><p><b>Gene structure.</b>
<i>OPA1</i> consists of 31 exons spanning more than 114 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Eight <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> have been described as a result of alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of exons 4, 4b, and 5b [<a class="bk_pop" href="#opa.REF.delettre.2001.584">Delettre et al 2001</a>]. For details see <a href="/books/NBK1248/#opa.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> There is a wide spectrum of pathogenic variants, with more than 213 reported to date (see <a href="/books/NBK1248/#opa.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>ClinVar</b>). The <i>OPA1</i> pathogenic variants are distributed throughout the coding sequence, but most are localized in exons 8-16 encoding the GTPase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and in the last two coding exons: 27 and 28); fewer pathogenic variants are found in exons 1 to 7. To date no pathogenic variants have been found in exons 4 and 4b, which are alternatively spliced. However, a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5b (c.740G&#x0003e;A) has been described in one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual [<a class="bk_pop" href="#opa.REF.cornille.2008.667">Cornille et al 2008</a>].</p><p>An ~325-bp Alu-element <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> located in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 7 of <i>OPA1</i> [<a href="/nuccore/224831242" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015560.2</a>] has been described as causing an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 in a family with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy (ADOA) [<a class="bk_pop" href="#opa.REF.gallus.2010.178">Gallus et al 2010</a>].</p><div id="opa.T.opa1_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>OPA1</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1248/table/opa.T.opa1_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__opa.T.opa1_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.740G&#x0003e;A&#x000a0;<sup>2</sup></td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg247His</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_130837.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_130837<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_570850.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_570850<wbr style="display:inline-block"></wbr>​.2</a> (isoform 8)</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1065+1G&#x0003e;T<br />(IVS12+1G&#x0003e;T)</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_3" rowspan="10" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/224831242" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_015560<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/224831243" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_056375<wbr style="display:inline-block"></wbr>​.2</a> (isoform 1)</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.728T&#x0003e;A</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu243Ter</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.983A&#x0003e;G&#x000a0;<sup>3</sup></td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1067_1068dup</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala357LeufsTer4</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1202G&#x0003e;A</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly401Asp</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1310A&#x0003e;G</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln437Arg</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1334G&#x0003e;A</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg445His</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1387_1392dup</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile463_Phe464dup</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2708_2711delTTAG</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val903GlyfsTer3</td></tr><tr><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2826delT</td><td headers="hd_h_opa.T.opa1_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg943GlufsTer25</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="opa.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="opa.TF.2.2"><p class="no_margin">In <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5b of alternative transcript that encodes isoform 8 (<a href="/books/NBK1248/#opa.molgen.TA">Table A</a>, <b>Gene</b>)</p></div></dd><dt>3. </dt><dd><div id="opa.TF.2.3"><p class="no_margin">Substitution in the antepenultimate nucleotide position of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9, which modifies the consensus sequence of the 5' donor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 9, resulting in an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> skipping of exon 9 [<a class="bk_pop" href="#opa.REF.baris.2003.656">Baris et al 2003</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Dynamin-like 120-kd protein (OPA1), encoded by <i>OPA1</i>, is a mitochondrial dynamin-related GTP protein of 960 amino acids. This is the first dynamin-related protein found to be involved in human disease. The dynamin-like 120-kd protein comprises a highly basic amino-terminal that provides mitochondrial targeting sequence (MTS), a dynamin-GTPase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, and a C-terminus of unknown function; the C-terminus differs from that of other dynamin family members in lacking a proline-rich region, a dynamin GTPase effector domain, and a pleckstrin homology domain; the C-terminus may therefore determine the specific functions of the dynamin-like 120-kd protein.</p><p>OPA1 appears to exert its function in mitochondrial biogenesis and stabilization of mitochondrial membrane integrity. Downregulation of <i>OPA1</i> leads to fragmentation of the mitochondrial network and dissipation of the mitochondrial membrane potential with cytochrome c release and caspase-dependent apoptosis [<a class="bk_pop" href="#opa.REF.olichon.2003.7743">Olichon et al 2003</a>]. Mitochondrial DNA (mtDNA) deletions have been identified in families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy who have complex multisystem involvement in addition to the optic neuropathy [<a class="bk_pop" href="#opa.REF.amatibonneau.2008.338">Amati-Bonneau et al 2008</a>, <a class="bk_pop" href="#opa.REF.ferraris.2008.125">Ferraris et al 2008</a>, <a class="bk_pop" href="#opa.REF.hudson.2008.329">Hudson et al 2008</a>] suggesting a role of OPA1 in mtDNA maintenance.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The functional consequences of pathogenic variants in <i>OPA1</i> are unknown. Since almost 50% of pathogenic variants predict protein truncation, dominant inheritance of the disease may result from <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> of dynamin-like 120-kd protein. However, pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants can also cause disease by a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> mechanism.</p><p>Interestingly, evidence for a <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> mechanism has been reported in all the multisystemic forms of the disease (ADOAD and "ADOA plus"). These disease forms have pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affecting the GTPase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> [<a class="bk_pop" href="#opa.REF.amatibonneau.2008.338">Amati-Bonneau et al 2008</a>]. In addition, one person with ADOA, who had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic <i>OPA1</i> missense variants located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8, was found to be severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by the disease [<a class="bk_pop" href="#opa.REF.pesch.2001.1359">Pesch et al 2001</a>], whereas her <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parents and sibs were less severely affected, suggesting a semi-dominant <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> in this family.</p></div></div><div id="opa.References"><h2 id="_opa_References_">References</h2><div id="opa.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="opa.REF.alward.2003.2">Alward WL. The OPA1 gene and optic neuropathy. <span><span class="ref-journal">Br J Ophthalmol. </span>2003;<span class="ref-vol">87</span>:2–3.</span> [<a href="/pmc/articles/PMC1771450/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1771450</span></a>] [<a href="/pubmed/12488251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12488251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.amatibonneau.2005.958">Amati-Bonneau P, Guichet A, Olichon A, Chevrollier A, Viala F, Miot S, Ayuso C, Odent S, Arrouet C, Verny C, Calmels MN, Simard G, Belenguer P, Wang J, Puel JL, Hamel C, Malthiery Y, Bonneau D, Lenaers G, Reynier P. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. <span><span class="ref-journal">Ann Neurol. </span>2005;<span class="ref-vol">58</span>:958–63.</span> [<a href="/pubmed/16240368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16240368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.amatibonneau.2008.338">Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, Carroccia R, Iommarini L, Labauge P, Figarella-Branger D, Marcorelles P, Furby A, Beauvais K, Letournel F, Liguori R, La Morgia C, Montagna P, Liguori M, Zanna C, Rugolo M, Cossarizza A, Wissinger B, Verny C, Schwarzenbacher R, Martin MA, Arenas J, Ayuso C, Garesse R, Lenaers G, Bonneau D, Carelli V. OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes. <span><span class="ref-journal">Brain. </span>2008;<span class="ref-vol">131</span>:338–51.</span> [<a href="/pubmed/18158317" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18158317</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.andrews.1999.231">Andrews RM, Griffiths PG, Johnson MA, Turnbull DM. Histochemical localisation of mitochondrial enzyme activity in human optic nerve and retina. <span><span class="ref-journal">Br J Ophthalmol. </span>1999;<span class="ref-vol">83</span>:231–5.</span> [<a href="/pmc/articles/PMC1722931/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1722931</span></a>] [<a href="/pubmed/10396204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10396204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.baloh.2007.422">Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. <span><span class="ref-journal">J Neurosci. </span>2007;<span class="ref-vol">27</span>:422–30.</span> [<a href="/pmc/articles/PMC6672077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6672077</span></a>] [<a href="/pubmed/17215403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17215403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.barbet.2005.e1">Barbet F, Hakiki S, Orssaud C, Gerber S, Perrault I, Hanein S, Ducroq D, Dufier J-L, Munnich A, Kaplan J, Rozet J-M. A third locus for dominant optic atrophy on chromosome 22q. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:e1.</span> [<a href="/pmc/articles/PMC1735912/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735912</span></a>] [<a href="/pubmed/15635063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15635063</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.baris.2003.656">Baris O, Delettre C, Amati-Bonneau P, Surget M-O, Charlin J-F, Catier A, Dollfus H, Jonveaux P, Bonneau D, Ayuso C, Maumenee I, Lorenz B, Mohammed SN, Tourmen Y, Malthiery Y, Hamel C, Reynier P. Fourteen novel OPA1 mutations in dominant optic atrophy and de novo mutations in isolated cases of optic atrophy. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">21</span>:656.</span> [<a href="/pubmed/14961560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14961560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.bristow.2002.791">Bristow EA, Griffiths PG, Andrews RM, Johnson MA, Turnbull DM. The distribution of mitochondrial activity in relation to optic nerve structure. <span><span class="ref-journal">Arch Ophthalmol. </span>2002;<span class="ref-vol">120</span>:791–6.</span> [<a href="/pubmed/12049585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12049585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.carelli.2007.a42">Carelli V, Schimpf S, Valentino ML, Fuhrmann N, Papke M, Schaich S, Tippmann S, Baumann B, Barboni P, Ghelli A, Bucchi L, Lodi R, Barbiroli B, Liguori R, Carroccia R, Villanova M, Montagna P, Baruzzi A, Wissinger B. Dominant optic atrophy (DOA) and sensorineural hearing loss: clinical, biochemical, spectroscopic and molecular genetic study of a large Italian pedigree linked to a new locus an chromosome 16. <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">68</span>:A42.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.chen.2005.26185">Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. <span><span class="ref-journal">J Biol Chem. </span>2005;<span class="ref-vol">280</span>:26185–92.</span> [<a href="/pubmed/15899901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15899901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.cornille.2008.667">Cornille K, Milea D, Amati-Bonneau P, Procaccio V, Zazoun L, Guillet V, El Achouri G, Delettre C, Gueguen N, Loiseau D, Muller A, Ferr&#x000e9; M, Chevrollier A, Wallace DC, Bonneau D, Hamel C, Reynier P, Lenaers G. Reversible optic neuropathy with OPA1 exon 5b mutation. <span><span class="ref-journal">Ann Neurol. </span>2008;<span class="ref-vol">63</span>:667–71.</span> [<a href="/pubmed/18360822" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18360822</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.cryns.2003.275">Cryns K, Sivakumaran TA, Van den Ouweland JM, Pennings RJ, Cremers CW, Flothmann K, Young TL, Smith RJ, Lesperance MM, Van Camp G. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:275–87.</span> [<a href="/pubmed/12955714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12955714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.delettre.2001.584">Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, Lenaers G, Belenguer P, Hamel CP. Mutation spectrum and splicing variants in the OPA1 gene. <span><span class="ref-journal">Hum Genet. </span>2001;<span class="ref-vol">109</span>:584–91.</span> [<a href="/pubmed/11810270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11810270</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.eiberg.2006.435">Eiberg H, Hansen L, Kjer B, Hansen T, Pedersen O, Bille M, Rosenberg T, Tranebjaerg L. Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:435–40.</span> [<a href="/pmc/articles/PMC2649014/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2649014</span></a>] [<a href="/pubmed/16648378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16648378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.ferraris.2008.125">Ferraris S, Clark S, Garelli E, Davidzon G, Moore SA, Kardon RH, Bienstock RJ, Longley MJ, Mancuso M, Rios PG, Hirano M, Copeland WC, DiMauro S. Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1. <span><span class="ref-journal">Arch Neurol. </span>2008;<span class="ref-vol">65</span>:125–31.</span> [<a href="/pmc/articles/PMC2364721/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2364721</span></a>] [<a href="/pubmed/18195150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18195150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.ferr_.2009.e692">Ferr&#x000e9; M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, Ayuso C, Defoort S, Vignal C, Zanlonghi X, Charlin JF, Kaplan J, Odent S, Hamel CP, Procaccio V, Reynier P, Amati-Bonneau P. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:E692–705.</span> [<a href="/pubmed/19319978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19319978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.gallus.2010.178">Gallus GN, Cardaioli E, Rufa A, Da Pozzo P, Bianchi S, D'Eramo C, Collura M, Tumino M, Pavone L, Federico A. Alu-element insertion in an OPA1 intron sequence associated with autosomal dominant optic atrophy. <span><span class="ref-journal">Mol Vis. </span>2010;<span class="ref-vol">16</span>:178–83.</span> [<a href="/pmc/articles/PMC2820104/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2820104</span></a>] [<a href="/pubmed/20157369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20157369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.hanein.2009.493">Hanein S, Perrault I, Roche O, Gerber S, Khadom N, Rio M, Boddaert N, Jean-Pierre M, Brahimi N, Serre V, Chretien D, Delphin N, Fares-Taie L, Lachheb S, Rotig A, Meire F, Munnich A, Dufier J-L, Kaplan J, Rozet J-M. TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">84</span>:493–8.</span> [<a href="/pmc/articles/PMC2667974/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2667974</span></a>] [<a href="/pubmed/19327736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19327736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.holder.1998.217">Holder GE, Votruba M, Carter AC, Bhattacharya SS, Fitzke FW, Moore AT. Electrophysiological findings in dominant optic atrophy (DOA) linking to the OPA1 locus on chromosome 3q 28-qter. <span><span class="ref-journal">Doc Ophthalmol. </span>1998;<span class="ref-vol">95</span>:217–28.</span> [<a href="/pubmed/10532406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10532406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.hollenbeck.2005.331">Hollenbeck PJ. Mitochondria and neurotransmission: evacuating the synapse. <span><span class="ref-journal">Neuron. </span>2005;<span class="ref-vol">47</span>:331–3.</span> [<a href="/pmc/articles/PMC2538582/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2538582</span></a>] [<a href="/pubmed/16055057" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16055057</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.hollenbeck.2005.5411">Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. <span><span class="ref-journal">J Cell Sci. </span>2005;<span class="ref-vol">118</span>:5411–9.</span> [<a href="/pmc/articles/PMC1533994/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1533994</span></a>] [<a href="/pubmed/16306220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16306220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.hudson.2008.329">Hudson G, Amati-Bonneau P, Blakely EL, Stewart JD, He LP, Schaefer AM, Griffiths PG, Ahlqvist K, Suomalainen A, Reynier P, McFarland R, Turnbull DM, Chinnery PF, Taylor RW. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. <span><span class="ref-journal">Brain. </span>2008;<span class="ref-vol">131</span>:329–37.</span> [<a href="/pubmed/18065439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18065439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.kamei.2005.4288">Kamei S, Chen-Kuo-Chang M, Cazevieille C, Lenaers G, Olichon A, Belenguer P, Roussignol G, Renard N, Eybalin M, Michelin A, Delettre C, Brabet P, Hamel CP. Expression of the Opa1 mitochondrial protein in retinal ganglion cells: its downregulation causes aggregation of the mitochondrial network. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2005;<span class="ref-vol">46</span>:4288–94.</span> [<a href="/pubmed/16249510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16249510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.kerrison.1999.805">Kerrison JB, Arnould VJ, Ferraz Sallum JM, Vagefi MR, Barmada MM, Li Y, Zhu D, Maumenee IH. Genetic heterogeneity of dominant optic atrophy, Kjer type: identification of a second locus on chromosome 18q12.2-12.3. <span><span class="ref-journal">Arch Ophthalmol. </span>1999;<span class="ref-vol">117</span>:805–10.</span> [<a href="/pubmed/10369594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10369594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.kjer.1996.3">Kjer B, Eiberg H, Kjer P, Rosenberg T. Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects. <span><span class="ref-journal">Acta Ophthalmol Scand. </span>1996;<span class="ref-vol">74</span>:3–7.</span> [<a href="/pubmed/8689476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8689476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.leruez.2013.e236">Leruez S, Milea D, Defoort-Dhellemmes S, Colin E, Crochet M, Procaccio V, Ferr&#x000e9; M, Lamblin J, Drouin V, Vincent-Delorme C, Lenaers G, Hamel C, Blanchet C, Juul G, Larsen M, Verny C, Reynier P, Amati-Bonneau P, Bonneau D. Sensorineural hearing loss in OPA1-linked disorders. <span><span class="ref-journal">Brain. </span>2013;<span class="ref-vol">136</span>:e236.</span> [<a href="/pubmed/23384603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23384603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.li.2005.208">Li C, Kosmorsky G, Zhang K, Katz BJ, Ge J, Traboulsi EI. Optic atrophy and sensorineural hearing loss in a family caused by an R445H OPA1 mutation. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">138A</span>:208–11.</span> [<a href="/pubmed/16158427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16158427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.li.2004.873">Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. <span><span class="ref-journal">Cell. </span>2004;<span class="ref-vol">119</span>:873–87.</span> [<a href="/pubmed/15607982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15607982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.lodi.2004.719">Lodi R, Tonon C, Valentino ML, Iotti S, Clementi V, Malucelli E, Barboni P, Longanesi L, Schimpf S, Wissinger B, Baruzzi A, Barbiroli B, Carelli V. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">56</span>:719–23.</span> [<a href="/pubmed/15505825" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15505825</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.marchbank.2002.e47">Marchbank NJ, Craig JE, Leek JP, Toohey M, Churchill AJ, Markham AF, Mackey DA, Toomes C, Inglehearn CF. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. <span><span class="ref-journal">J Med Genet. </span>2002;<span class="ref-vol">39</span>:e47.</span> [<a href="/pmc/articles/PMC1735190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735190</span></a>] [<a href="/pubmed/12161614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12161614</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.meire.1985.91">Meire F, De Laey JJ, de Bie S, van Staey M, Matton MT. Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO). <span><span class="ref-journal">Ophthalmic Paediatr Genet. </span>1985;<span class="ref-vol">5</span>:91–7.</span> [<a href="/pubmed/4058877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4058877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.nakamura.2006.483">Nakamura M, Lin J, Ueno S, Asaoka R, Hirai T, Hotta Y, Miyake Y, Terasaki H. Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy. <span><span class="ref-journal">Ophthalmology. </span>2006;<span class="ref-vol">113</span>:483–8.e1.</span> [<a href="/pubmed/16513463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16513463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.olichon.2003.7743">Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, Lenaers G. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:7743–6.</span> [<a href="/pubmed/12509422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12509422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.payne.2004.749">Payne M, Yang Z, Katz BJ, Warner JE, Weight CJ, Zhao Y, Pearson ED, Treft RL, Hillman T, Kennedy RJ, Meire FM, Zhang K. Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1. <span><span class="ref-journal">Am J Ophthalmol. </span>2004;<span class="ref-vol">138</span>:749–55.</span> [<a href="/pubmed/15531309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15531309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.pesch.2001.1359">Pesch UE, Leo-Kottler B, Mayer S, Jurklies B, Kellner U, Apfelstedt-Sylla E, Zrenner E, Alexander C, Wissinger B. OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1359–68.</span> [<a href="/pubmed/11440988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11440988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.puomila.2005.337">Puomila A, Huoponen K, Mantyjarvi M, Hamalainen P, Paananen R, Sankila EM, Savontaus ML, Somer M, Nikoskelainen E. Dominant optic atrophy: correlation between clinical and molecular genetic studies. <span><span class="ref-journal">Acta Ophthalmol Scand. </span>2005;<span class="ref-vol">83</span>:337–46.</span> [<a href="/pubmed/15948788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15948788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.reynier.2004.e110">Reynier P, Amati-Bonneau P, Verny C, Olichon A, Simard G, Guichet A, Bonnemains C, Malecaze F, Malinge MC, Pelletier JB, Calvas P, Dollfus H, Belenguer P, Malthi&#x000e8;ry Y, Lenaers G, Bonneau D. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:e110.</span> [<a href="/pmc/articles/PMC1735897/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735897</span></a>] [<a href="/pubmed/15342707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15342707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.shimizu.2003.256">Shimizu S, Mori N, Kishi M, Sugata H, Tsuda A, Kubota N. A novel mutation in the OPA1 gene in a Japanese patient with optic atrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>2003;<span class="ref-vol">135</span>:256–7.</span> [<a href="/pubmed/12566046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12566046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.thiselton.2002.1715">Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, Andreasson S, Van Regemorter N, Munier FL, Moore AT, Bhattacharya SS, Votruba M. A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2002;<span class="ref-vol">43</span>:1715–24.</span> [<a href="/pubmed/12036970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12036970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.toomes.2001.1369">Toomes C, Marchbank NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, Vize CJ, Desai SP, Black GC, Patel N, Teimory M, Markham AF, Inglehearn CF, Churchill AJ. Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1369–78.</span> [<a href="/pubmed/11440989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11440989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.treft.1984.908">Treft RL, Sanborn GE, Carey J, Swartz M, Crisp D, Wester DC, Creel D. Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy. A new syndrome. <span><span class="ref-journal">Ophthalmology. </span>1984;<span class="ref-vol">91</span>:908–15.</span> [<a href="/pubmed/6493699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6493699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.voo.2003.670">Voo I, Allf BE, Udar N, Silva-Garcia R, Vance J, Small KW. Hereditary motor and sensory neuropathy type VI with optic atrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>2003;<span class="ref-vol">136</span>:670–7.</span> [<a href="/pubmed/14516807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14516807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.votruba.2003.48">Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. <span><span class="ref-journal">Br J Ophthalmol. </span>2003;<span class="ref-vol">87</span>:48–53.</span> [<a href="/pmc/articles/PMC1771445/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1771445</span></a>] [<a href="/pubmed/12488262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12488262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.wang.2003.2">Wang L, Dong J, Cull G, Fortune B, Cioffi GA. Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2003;<span class="ref-vol">44</span>:2–9.</span> [<a href="/pubmed/12506048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12506048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="opa.REF.z_chner.2006.276">Z&#x000fc;chner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, Tournev I, Verhoeven K, Langerhorst CT, de Visser M, Baas F, Bird T, Timmerman V, Shy M, Vance JM. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:276–81.</span> [<a href="/pubmed/16437557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16437557</span></a>]</div></li></ul></div></div><div id="opa.Chapter_Notes"><h2 id="_opa_Chapter_Notes_">Chapter Notes</h2><div id="opa.Author_Notes"><h3>Author Notes</h3><p><b>Institute for Neurosciences of Montpellier</b></p><p>Web: <a href="http://www.inmfrance.com/us/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Institut des Neurosciences de Montpellier</a></p><p><b>MAOLYA Center (National Reference Center for Genetic Sensory Disorders)</b></p><p>Ophthalmology Service, 1<sup>er</sup> floor</p><p>H&#x000f4;pital Guy de Chauliac</p><p>80, Avenue Augustin Fliche</p><p>34 295 Montpellier Cedex 5, France</p><p>Phone: (33/0) 467&#x000a0;330 278 / (33/0) 467&#x000a0;330 279</p><p>Email: <a href="mailto:dev@null" data-email="rf.reilleptnom-uhc@gsm" class="oemail">rf.reilleptnom-uhc@gsm</a></p><p>Web: <a href="http://www.sensgene.com/en/reference-centers/maolya-reference-center-rare-diseases-genetic-sensory-diseases" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sensgene.com</a></p></div><div id="opa.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 November 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 July 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>24 March 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/targeted-mutation-analysis/">targeted mutation analysis</a> for Danish founder mutation available clinically</div></li><li class="half_rhythm"><div>7 August 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>13 July 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>23 October 2006 (cdc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1248</span><span class="label">PMID: <a href="/pubmed/20301426" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301426</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/opmd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ofd1/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1248&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1248/?report=reader">PubReader</a></li><li><a href="/books/NBK1248/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1248" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1248" style="display:none" title="Cite this Page"><div class="bk_tt">Delettre-Cribaillet C, Hamel CP, Lenaers G. Optic Atrophy Type 1. 2007 Jul 13 [Updated 2015 Nov 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1248/pdf/Bookshelf_NBK1248.pdf">PDF version of this page</a> (469K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#opa.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#opa.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#opa.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#opa.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#opa.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#opa.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#opa.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#opa.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#opa.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#opa.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#opa.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4976[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">OPA1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1248+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1485160" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1485160" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1485160" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1485160" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22776096" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dominant optic atrophy.</a><span class="source">[Orphanet J Rare Dis. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Dominant optic atrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lenaers G, Hamel C, Delettre C, Amati-Bonneau P, Procaccio V, Bonneau D, Reynier P, Milea D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2012 Jul 9; 7:46. Epub 2012 Jul 9.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301353" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leber Hereditary Optic Neuropathy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leber Hereditary Optic Neuropathy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Yu-Wai-Man P, Chinnery PF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12488262" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy.</a><span class="source">[Br J Ophthalmol. 2003]</span><div class="brieflinkpop offscreen_noflow">Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Votruba M, Thiselton D, Bhattacharya SS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br J Ophthalmol. 2003 Jan; 87(1):48-53. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16513463" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy.</a><span class="source">[Ophthalmology. 2006]</span><div class="brieflinkpop offscreen_noflow">Novel mutations in the OPA1 gene and associated clinical features in Japanese patients with optic atrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nakamura M, Lin J, Ueno S, Asaoka R, Hirai T, Hotta Y, Miyake Y, Terasaki H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ophthalmology. 2006 Mar; 113(3):483-488.e1. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11535456" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Disc excavation in dominant optic atrophy: differentiation from normal tension glaucoma.</a><span class="source">[Ophthalmology. 2001]</span><div class="brieflinkpop offscreen_noflow">Disc excavation in dominant optic atrophy: differentiation from normal tension glaucoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fournier AV, Damji KF, Epstein DL, Pollock SC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ophthalmology. 2001 Sep; 108(9):1595-602. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301426" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301426" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0415f675f66d18aa5511e3">Optic Atrophy Type 1 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Optic Atrophy Type 1 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:07:50-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DD866E04079410000000006120239&amp;ncbi_session=CE8DD866E0415F51_1554SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1248%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1248&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1248/&amp;ncbi_pagename=Optic Atrophy Type 1 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DD866E0415F51_1554SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>